[Treatment of dementia with Lewy bodies].
Dementia with Lewy bodies (DLB) is known for its partial resistance and hypersensitivity to some treatments, but DLB is treatable with cholinesterase inhibitors, sometimes better than in Alzheimer's disease. Cholinesterase inhibitors have a symptomatic effect on cognition and behavior. Nevertheless, new antipsychotics are sometimes also useful to manage psychotic symptoms. Although DLB patients respond less well to levodopa than patients with Parkinson's disease, 75 percent of DLB patients improve with levodopa, which is the best-tolerated dopaminergic agent. Nonpharmacological strategies include speech therapy, physiotherapy, psychotherapy, and educational support groups for care givers.
Lebert
F
F
Centre de la Mémoire, EA 2691, Clinique Neurologique, Hôpital Roger Salengro, Centre Hospitalier Universitaire, Lille. f-lebert@chru-lille.fr
Le Rhun
E
E
D000978:Antiparkinson Agents / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use; D001342:Autonomic Nervous System Diseases / Q000188:drug therapy / Q000209:etiology; D001480:Basal Ganglia Diseases / Q000139:chemically induced / Q000188:drug therapy / Q000628:therapy; D019090:Case Management; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D006212:Hallucinations / Q000209:etiology / Q000628:therapy; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D020961:Lewy Body Disease / Q000188:drug therapy / Q000523:psychology / Q000628:therapy*; D001523:Mental Disorders / Q000209:etiology / Q000628:therapy; D019964:Mood Disorders / Q000209:etiology / Q000628:therapy; D018697:Nootropic Agents / Q000627:therapeutic use; D026741:Physical Therapy Modalities; D012893:Sleep Wake Disorders / Q000209:etiology / Q000628:therapy; D013070:Speech Therapy
D000978:Antiparkinson Agents; D014150:Antipsychotic Agents; D002800:Cholinesterase Inhibitors; D018697:Nootropic Agents; D007980:Levodopa